{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:01:43Z","timestamp":1792047703747,"version":"4.4.0"},"reference-count":145,"publisher":"American Psychiatric Association Publishing","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AJP"],"published-print":{"date-parts":[[2000,9,1]]},"DOI":"10.1176\/appi.ajp.157.9.1379","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T18:10:43Z","timestamp":1034359843000},"page":"1379-1389","source":"Crossref","is-referenced-by-count":341,"title":["Depression in Schizophrenia: Perspective in the Era of \u201cAtypical\u201d Antipsychotic Agents"],"prefix":"10.1176","volume":"157","author":[{"given":"Samuel G.","family":"Siris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"230","reference":[{"key":"atypb1","unstructured":"Burrows GD, Judd LL, Fleischhacker WW, Andreasen NC: Current concepts of affective disorders in schizophrenia. J Clin Psychiatry Monograph 1998; 16:2\u20138"},{"key":"R1579BABBIIFD","doi-asserted-by":"crossref","unstructured":"McGlashan TH, Carpenter WJ Jr: Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 33:231\u2013239","DOI":"10.1001\/archpsyc.1976.01770020065011"},{"key":"R1579BABICGHJ","doi-asserted-by":"crossref","unstructured":"Siris SG: Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17:75\u201398","DOI":"10.1093\/schbul\/17.1.75"},{"key":"R1579BABCIJCE","doi-asserted-by":"crossref","unstructured":"Falloon I, Watt DC, Shepherd M: A comparative controlled trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8:59\u201370","DOI":"10.1017\/S0033291700006632"},{"key":"R1579BABHDGJI","doi-asserted-by":"crossref","unstructured":"Mandel MR, Severe JB, Schooler NR, Gelenberg AJ, Mieske M: Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1982; 39:197\u2013203","DOI":"10.1001\/archpsyc.1982.04290020051010"},{"key":"R1579BABCCFIF","doi-asserted-by":"crossref","unstructured":"Roy A, Thompson R, Kennedy S: Depression in chronic schizophrenia. Br J Psychiatry 1983; 142:465\u2013470","DOI":"10.1192\/bjp.142.5.465"},{"key":"R1579BABJECAA","doi-asserted-by":"crossref","unstructured":"Johnson DAW: The significance of depression in the prediction of relapse in chronic schizophrenia. Br J Psychiatry 1988; 152:320\u2013323","DOI":"10.1192\/bjp.152.3.320"},{"key":"R1579BABIFFCF","doi-asserted-by":"crossref","unstructured":"Birchwood M, Mason R, Macmillan F, Healy J: Depression, demoralization and control over psychotic illness: a comparison of depressed and non-depressed patients with a chronic psychosis. Psychol Med 1993; 23:387\u2013395","DOI":"10.1017\/S0033291700028488"},{"key":"R1579BABFDEDF","doi-asserted-by":"crossref","unstructured":"Caldwell CB, Gottesman II: Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990; 16:571\u2013589","DOI":"10.1093\/schbul\/16.4.571"},{"key":"R1579BABEEHFJ","doi-asserted-by":"crossref","unstructured":"Heil\u00e4 H, Isomets\u00e4 ET, Henriksson MM, Heikkinen ME, Marttunen MJ, L\u00f6nnqvist JK: Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997; 154:1235\u20131242","DOI":"10.1176\/ajp.154.9.1235"},{"key":"R1579BABFDIGA","doi-asserted-by":"crossref","unstructured":"Fenton WS, McGlashan TH, Victor BJ, Blyler CR: Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997; 154:199\u2013204","DOI":"10.1176\/ajp.154.2.199"},{"key":"R1579BABGIDAB","doi-asserted-by":"crossref","unstructured":"Norman RMG, Malla AK, Cortese L, Diaz F: Aspects of dysphoria and symptoms of schizophrenia. Psychol Med 1998; 28:1433\u20131441","DOI":"10.1017\/S003329179800751X"},{"key":"atypb2","doi-asserted-by":"crossref","unstructured":"M\u00fcller MJ, Wetzel H: Dimensionality of depression in acute schizophrenia: a methodological study using the Bech-Rafaelsen Melancholia Scale (BRMES). J Psychiatr Res 1998; 32:369\u2013378","DOI":"10.1016\/S0022-3956(98)00029-6"},{"key":"atypb3","doi-asserted-by":"crossref","unstructured":"Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M: Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52:341\u2013351","DOI":"10.1001\/archpsyc.1995.03950170015003"},{"key":"R1579BABJJJDI","doi-asserted-by":"crossref","unstructured":"Lindenmeyer JP, Grochowski S, Hyman RB: Five factor model of schizophrenia: replication across samples. Schizophr Res 1995; 14:229\u2013234","DOI":"10.1016\/0920-9964(94)00041-6"},{"key":"R1579BABCBFHH","doi-asserted-by":"crossref","unstructured":"Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieberman J: Depression in first-episode schizophrenia. Am J Psychiatry 1993; 150:1643\u20131648","DOI":"10.1176\/ajp.150.11.1643"},{"key":"R1579BABHGDGF","doi-asserted-by":"crossref","unstructured":"Hirsch SR, Jolley AG, Barnes TRE, Liddle PF, Curson DA, Patel A, York A, Bercu S, Patel M: Dysphoric and depressive symptoms in chronic schizophrenia. Schizophr Res 1989; 2:259\u2013264","DOI":"10.1016\/0920-9964(89)90002-9"},{"key":"R1579BABECGDI","doi-asserted-by":"crossref","unstructured":"Bartels SJ, Drake RE: Depressive symptoms in schizophrenia: comprehensive differential diagnosis. Compr Psychiatry 1988; 29:467\u2013483","DOI":"10.1016\/0010-440X(88)90062-4"},{"key":"R1579BABEBBEA","doi-asserted-by":"crossref","unstructured":"Dalack GW, Healy DJ, Meador-Woodruff JH: Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998; 155:1490\u20131501","DOI":"10.1176\/ajp.155.11.1490"},{"key":"R1579BABHBBFF","doi-asserted-by":"crossref","unstructured":"Andreasen NC, Olsen S: Negative v positive schizophrenia: definition and validation. Arch Gen Psychiatry 1982; 39:789\u2013794","DOI":"10.1001\/archpsyc.1982.04290070025006"},{"key":"atypb4","doi-asserted-by":"crossref","unstructured":"Carpenter WT Jr, Heinrichs DW, Alphs LD: Treatment of negative symptoms. Schizophr Bull 1985; 11:440\u2013452","DOI":"10.1093\/schbul\/11.3.440"},{"key":"atypb5","doi-asserted-by":"crossref","unstructured":"Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Casey E: Postpsychotic depression and negative symptoms: an investigation of syndromal overlap. Am J Psychiatry 1988; 145:1532\u20131537","DOI":"10.1176\/ajp.145.12.1532"},{"key":"R1579BABHGBCI","doi-asserted-by":"crossref","unstructured":"Bermanzohn PC, Siris SG: Akinesia: a syndrome common to parkinsonism, retarded depression, and negative symptoms. Compr Psychiatry 1992; 33:221\u2013232","DOI":"10.1016\/0010-440X(92)90045-R"},{"key":"R1579BABEDGCD","doi-asserted-by":"crossref","unstructured":"Lindenmayer J-P, Grochowski S, Kay SR: Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms. Compr Psychiatry 1991; 32:528\u2013533","DOI":"10.1016\/0010-440X(91)90032-8"},{"key":"atypb6","doi-asserted-by":"crossref","unstructured":"Norman RMG, Malla AK: Dysphoric mood and symptomatology in schizophrenia. Psychol Med 1991; 21:897\u2013903","DOI":"10.1017\/S0033291700029883"},{"key":"atypb7","doi-asserted-by":"crossref","unstructured":"Kuck J, Zisook S, Moranville JT, Heaton RK, Raff DL: Negative symptomatology in schizophrenic outpatients. J Nerv Ment Dis 1992; 180:510\u2013515","DOI":"10.1097\/00005053-199208000-00006"},{"key":"R1579BABGFJDA","doi-asserted-by":"crossref","unstructured":"Kibel DA, Laffont I, Liddle PF: The composition of the negative syndrome of chronic schizophrenia. Br J Psychiatry 1993; 162:744\u2013750","DOI":"10.1192\/bjp.162.6.744"},{"key":"R1579BABGFGJF","doi-asserted-by":"crossref","unstructured":"Wise RA: Neuroleptics and operant behaviour: the anhedonia hypothesis. Behav Brain Sci 1982; 5:39\u201387","DOI":"10.1017\/S0140525X00010372"},{"key":"R1579BABDEIBB","doi-asserted-by":"crossref","unstructured":"Harrow M, Yonan CA, Sands JR, Marengo J: Depression in schizophrenia: are neuroleptics, akinesia, or anhedonia involved? Schizophr Bull 1994; 20:327\u2013338","DOI":"10.1093\/schbul\/20.2.327"},{"key":"R1579BABGHEDA","doi-asserted-by":"crossref","unstructured":"Awad GA: Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609\u2013618","DOI":"10.1093\/schbul\/19.3.609"},{"key":"R1579BABEEBAJ","doi-asserted-by":"crossref","unstructured":"DeAlarcon R, Carney MWP: Severe depressive mood changes following slow-release intramuscular fluphenazine injection. Br Med J 1969; 3:564\u2013567","DOI":"10.1136\/bmj.3.5670.564"},{"key":"atypb8","doi-asserted-by":"crossref","unstructured":"Floru L, Heinrich K, Wittek F: The problem of post-psychotic schizophrenic depressions and their pharmacological induction. Int Pharmacopsychiatry 1975; 10:230\u2013239","DOI":"10.1159\/000468199"},{"key":"atypb9","doi-asserted-by":"crossref","unstructured":"Galdi J, Rieder RO, Silber D, Bonato RR: Genetic factors in the response to neuroleptics in schizophrenia: a pharmacogenetic study. Psychol Med 1981; 11:713\u2013728","DOI":"10.1017\/S0033291700041210"},{"key":"atypb10","doi-asserted-by":"crossref","unstructured":"Johnson DAW: Depressions in schizophrenia: some observations on prevalence, etiology, and treatment. Acta Psychiatr Scand Suppl 1981; 291:137\u2013144","DOI":"10.1111\/j.1600-0447.1981.tb02466.x"},{"key":"R1579BABCJABA","doi-asserted-by":"crossref","unstructured":"Galdi J: The causality of depression in schizophrenia. Br J Psychiatry 1983; 142:621\u2013625","DOI":"10.1192\/bjp.142.6.621"},{"key":"R1579BABGFGAJ","doi-asserted-by":"crossref","unstructured":"Krakowski M, Czobor P, Volavka J: Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes. Psychiatry Res 1997; 71:19\u201326","DOI":"10.1016\/S0165-1781(97)03076-X"},{"key":"R1579BABHAAGI","doi-asserted-by":"crossref","unstructured":"Browne S, Garavan J, Gervin M, Roe M, Larkin C, O\u2019Callighan E: Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186:74\u201378","DOI":"10.1097\/00005053-199802000-00002"},{"key":"R1579BABCFEBB","doi-asserted-by":"crossref","unstructured":"Knights A, Hirsch SR: \u201cRevealed\u201d depression and drug treatment for schizophrenia. Arch Gen Psychiatry 1981; 38:806\u2013811","DOI":"10.1001\/archpsyc.1981.01780320086010"},{"key":"atypb11","doi-asserted-by":"crossref","unstructured":"M\u00f6ller HJ, vonZerssen D: Depressive states occurring during the neuroleptic treatment of schizophrenia. Schizophr Bull 1982; 8:109\u2013117","DOI":"10.1093\/schbul\/8.1.109"},{"key":"atypb12","doi-asserted-by":"crossref","unstructured":"Leff J, Tress K, Edwards B: The clinical course of depressive symptoms in schizophrenia. Schizophr Res 1988; 1:25\u201330","DOI":"10.1016\/0920-9964(88)90036-9"},{"key":"R1579BABGCAGI","doi-asserted-by":"crossref","unstructured":"Green MF, Nuechterlein KH, Ventura J, Mintz J: The temporal relationship between depressive and psychotic symptoms in recent-onset schizophrenia. Am J Psychiatry 1990; 147:179\u2013182","DOI":"10.1176\/ajp.147.2.179"},{"key":"R1579BABEBIIB","doi-asserted-by":"crossref","unstructured":"Nakaya M, Ohmori K, Komahashi T, Suwa H: Depressive symptoms in acute schizophrenic inpatients. Schizophr Res 1997; 25:131\u2013139","DOI":"10.1016\/S0920-9964(97)00014-5"},{"key":"R1579BABEAGIF","doi-asserted-by":"crossref","unstructured":"Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JT: Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Br Med J 1973; 1:633\u2013637","DOI":"10.1136\/bmj.1.5854.633"},{"key":"atypb13","unstructured":"Wistedt B, Palmstierna T: Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. J Clin Psychiatry 1983; 44:369\u2013371"},{"key":"R1579BABFGIDJ","doi-asserted-by":"crossref","unstructured":"Hogarty GE, Munetz MR: Pharmacogenic depression among outpatient schizophrenic patients: a failure to substantiate. J Clin Psychopharmacol 1984; 4:17\u201324","DOI":"10.1097\/00004714-198402000-00003"},{"key":"R1579BABIIBCE","unstructured":"Roy A: Do neuroleptics cause depression? Biol Psychiatry 1984; 19:777\u2013781"},{"key":"atypb14","doi-asserted-by":"crossref","unstructured":"Berrios GE, Bulbena A: Post psychotic depression: the Fulbourn cohort. Acta Psychiatr Scand 1987; 76:89\u201393","DOI":"10.1111\/j.1600-0447.1987.tb02866.x"},{"key":"atypb15","doi-asserted-by":"crossref","unstructured":"Siris SG, Strahan A, Mandeli J, Cooper TB, Casey E: Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression. Schizophr Res 1988; 1:31\u201335","DOI":"10.1016\/0920-9964(88)90037-0"},{"key":"atypb16","doi-asserted-by":"crossref","unstructured":"Barnes TR, Curson DA, Liddle PF, Patel M: The nature and prevalence of depression in chronic schizophrenic in-patients. Br J Psychiatry 1989; 154:486\u2013491","DOI":"10.1192\/bjp.154.4.486"},{"key":"R1579BABCACEA","doi-asserted-by":"crossref","unstructured":"Bandelow B, Muller P, Gaebel WE: Depressive syndromes in schizophrenic patients after discharge from hospital. Eur Arch Psychiatry Clin Neurosci 1991; 240:113\u2013120","DOI":"10.1007\/BF02189981"},{"key":"R1579BABEBBFH","doi-asserted-by":"crossref","unstructured":"Davis KL, Kahn RS, Ko G, Davidson M: Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474\u20131486","DOI":"10.1176\/ajp.148.11.1474"},{"key":"R1579BABICCCI","doi-asserted-by":"crossref","unstructured":"Rifkin A, Quitkin F, Klein DF: Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 1975; 32:672\u2013674","DOI":"10.1001\/archpsyc.1975.01760230138011"},{"key":"R1579BABDCGDF","doi-asserted-by":"crossref","unstructured":"Rifkin A, Quitkin F, Kane JM, Klein DF: Are prophylactic antiparkinson drugs necessary? Arch Gen Psychiatry 1978; 35:483\u2013489","DOI":"10.1001\/archpsyc.1978.01770280093010"},{"key":"R1579BABGEEJD","doi-asserted-by":"crossref","unstructured":"Van Putten T, May PRA: \u201cAkinetic depression\u201d in schizophrenia. Arch Gen Psychiatry 1978; 35:1101\u20131107","DOI":"10.1001\/archpsyc.1978.01770330075006"},{"key":"R1579BABBEAFB","doi-asserted-by":"crossref","unstructured":"Van Putten T: The many faces of akathisia. Compr Psychiatry 1975; 16:43\u201347","DOI":"10.1016\/0010-440X(75)90019-X"},{"key":"R1579BABDGAAE","doi-asserted-by":"crossref","unstructured":"Halstead SM, Barnes TRE, Speller JC: Akathisia: prevalence and associated dysphoria in an in-patient population with chronic schizophrenia. Br J Psychiatry 1994; 164:177\u2013183","DOI":"10.1192\/bjp.164.2.177"},{"key":"R1579BABBHICI","doi-asserted-by":"crossref","unstructured":"Shear K, Frances A, Weiden P: Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983; 3:235\u2013236","DOI":"10.1097\/00004714-198308000-00006"},{"key":"R1579BABDHAAF","doi-asserted-by":"crossref","unstructured":"Drake RE, Ehrlich J: Suicide attempts associated with akathisia. Am J Psychiatry 1985; 142:499\u2013501","DOI":"10.1176\/ajp.142.4.499"},{"key":"R1579BABHJFIA","doi-asserted-by":"crossref","unstructured":"Liddle PF, Barnes TRE, Curson DA, Patel M: Depression and the experience of psychological deficits in schizophrenia. Acta Psychiatr Scand 1993; 88:243\u2013247","DOI":"10.1111\/j.1600-0447.1993.tb03450.x"},{"key":"R1579BABCIADF","doi-asserted-by":"crossref","unstructured":"Lysaker PH, Bell MD, Bioty SM, Zito WS: The frequency of associations between positive and negative symptoms and dysphoria in schizophrenia. Compr Psychiatry 1995; 36:113\u2013117","DOI":"10.1016\/S0010-440X(95)90105-1"},{"key":"atypb17","doi-asserted-by":"crossref","unstructured":"Klein DF: Endogenomorphic depression: a conceptual and terminological revision. Arch Gen Psychiatry 1974; 31:447\u2013454","DOI":"10.1001\/archpsyc.1974.01760160005001"},{"key":"R1579BABBFBFA","doi-asserted-by":"crossref","unstructured":"deFigueiredo JM: Depression and demoralization: phenomenologic differences and research perspectives. Compr Psychiatry 1993; 34:308\u2013311","DOI":"10.1016\/0010-440X(93)90016-W"},{"key":"R1579BABJAEEB","doi-asserted-by":"crossref","unstructured":"Docherty JP, van Kammen DP, Siris SG, Marder SR: Stages of onset of schizophrenic psychosis. Am J Psychiatry 1978; 135:420\u2013426","DOI":"10.1176\/ajp.135.4.420"},{"key":"atypb18","doi-asserted-by":"crossref","unstructured":"Herz MI, Melville C: Relapse in schizophrenia. Am J Psychiatry 1980; 137:801\u2013805","DOI":"10.1176\/ajp.137.7.801"},{"key":"atypb19","doi-asserted-by":"crossref","unstructured":"Subotnik KL, Nuechterlein KH: Prodromal signs and symptoms of schizophrenic relapse. J Abnorm Psychol 1988; 97:405\u2013412","DOI":"10.1037\/0021-843X.97.4.405"},{"key":"R1579BABFADDF","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Andersen SW, Tran PV: The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46:365\u2013373","DOI":"10.1016\/S0006-3223(99)00049-9"},{"key":"R1579BABJBDIE","doi-asserted-by":"crossref","unstructured":"Malla AK, Norman RMG: Prodromal symptoms in schizophrenia. Br J Psychiatry 1994; 164:287\u2013293","DOI":"10.1192\/bjp.164.4.487"},{"key":"R1579BABHJHCH","doi-asserted-by":"crossref","unstructured":"Kasanin J: The acute schizoaffective psychoses. Am J Psychiatry 1933; 90:97\u2013126","DOI":"10.1176\/ajp.90.1.97"},{"key":"R1579BABGGGII","doi-asserted-by":"crossref","unstructured":"Levitt JJ, Tsuang MT: The heterogeneity of schizoaffective disorder: implications for treatment. Am J Psychiatry 1988; 145:926\u2013936","DOI":"10.1176\/ajp.145.8.926"},{"key":"atypb20","doi-asserted-by":"crossref","unstructured":"Coryell W, Keller M, Lavori P, Endicott J: Affective syndromes, psychotic features, and prognosis, I: depression. Arch Gen Psychiatry 1990; 47:651\u2013657","DOI":"10.1001\/archpsyc.1990.01810190051007"},{"key":"R1579BABBDDFA","doi-asserted-by":"crossref","unstructured":"Taylor MA: Are schizophrenia and affective disorder related? a selective literature review. Am J Psychiatry 1992; 149:22\u201332","DOI":"10.1176\/ajp.149.1.22"},{"key":"R1579BABDGEFH","doi-asserted-by":"crossref","unstructured":"Zubin J, Spring B: Vulnerability: a new view of schizophrenia. J Abnorm Psychol 1977; 86:103\u2013126","DOI":"10.1037\/\/0021-843X.86.2.103"},{"key":"R1579BABFCDFB","doi-asserted-by":"crossref","unstructured":"Nuechterlein KH, Dawson MD: A heuristic vulnerability\/stress model of schizophrenic episodes. Schizophr Bull 1984; 10:300\u2013312","DOI":"10.1093\/schbul\/10.2.300"},{"key":"R1579BABEAIIF","doi-asserted-by":"crossref","unstructured":"Norman RMG, Malla AK: Correlation over time between dysphoric mood and symptomatology in schizophrenia. Compr Psychiatry 1994; 35:34\u201338","DOI":"10.1016\/0010-440X(94)90167-8"},{"key":"R1579BABGFJCI","doi-asserted-by":"crossref","unstructured":"Sax KW, Strakowski SM, Keck PE, Upadhyaya VH, West SA, McElroy SL: Relationships among negative, positive, and depressive symptoms in schizophrenia and psychotic depression. Br J Psychiatry 1996; 168:68\u201371","DOI":"10.1192\/bjp.168.1.68"},{"key":"R1579BABBJAGC","doi-asserted-by":"crossref","unstructured":"Siris SG, Bermanzohn PC, Mason SE, Shuwall MA: Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 1994; 51:109\u2013115","DOI":"10.1001\/archpsyc.1994.03950020033003"},{"key":"R1579BABJBEII","doi-asserted-by":"crossref","unstructured":"Peuskens J: Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-center, double-blind, parallel group study versus haloperidol. Br J Psychiatry 1995; 166:712\u2013726","DOI":"10.1192\/bjp.166.6.712"},{"key":"R1579BABFEAAJ","unstructured":"Tandon R, Harrigan E, Zorn SH: Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4:159\u2013177"},{"key":"atypb21","doi-asserted-by":"crossref","unstructured":"Borison RL, Arvanitis LA, Miller BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16:158\u2013169","DOI":"10.1097\/00004714-199604000-00008"},{"key":"R1579BABBBIFF","doi-asserted-by":"crossref","unstructured":"Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25\u201340","DOI":"10.1097\/00004714-199302000-00004"},{"key":"R1579BABJIACF","doi-asserted-by":"crossref","unstructured":"Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825\u2013835","DOI":"10.1176\/ajp.151.6.825"},{"key":"R1579BABDGGFH","unstructured":"Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA III, Heym J: Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275:101\u2013113"},{"key":"R1579BABDEJAB","unstructured":"Jones H: Risperidone: a review of its pharmacology and use in the treatment of schizophrenia. J Serotonin Res 1997; 4:17\u201328"},{"key":"atypb22","unstructured":"Meltzer HY, Matsubara S, Lee JC: Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 25:238\u2013246"},{"key":"R1579BABBJGFH","doi-asserted-by":"crossref","unstructured":"Deutch AY, Moghaddam B, Innis RB, Krystal JH, Aghajanian GK, Bunney BS, Charney DS: Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schizophr Res 1991; 4:121\u2013156","DOI":"10.1016\/0920-9964(91)90030-U"},{"key":"R1579BABCAFJH","doi-asserted-by":"crossref","unstructured":"Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111\u2013123","DOI":"10.1016\/0893-133X(95)00069-P"},{"key":"atypb23","doi-asserted-by":"crossref","unstructured":"Buchanan RW: Clozapine: efficacy and safety. Schizophr Bull 1995; 21:579\u2013591","DOI":"10.1093\/schbul\/21.4.579"},{"key":"R1579BABHHDDD","doi-asserted-by":"crossref","unstructured":"Kane JM, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789\u2013796","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"atypb24","doi-asserted-by":"crossref","unstructured":"M\u00f6ller HJ, Muller H, Borison R, Schooler NR, Chouinard G: A path analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study. Eur Arch Clin Neurosci 1995; 245:45\u201349","DOI":"10.1007\/BF02191543"},{"key":"R1579BABEGHBA","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457\u2013465","DOI":"10.1176\/ajp.154.4.457"},{"key":"R1579BABJHCHB","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Sanger TM: Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154:466\u2013474","DOI":"10.1176\/ajp.154.4.466"},{"key":"R1579BABFBDCH","doi-asserted-by":"crossref","unstructured":"Franz M, Lis S, Pluddemann K, Gallhofer B: Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry 1997; 170:422\u2013425","DOI":"10.1192\/bjp.170.5.422"},{"key":"R1579BABFGAAD","unstructured":"Weaver MG: Olanzapine\u2014pharmacology and clinical evaluation of a new atypical antipsychotic. J Serotonin Res 1997; 4:145\u2013157"},{"key":"R1579BABFJJDA","doi-asserted-by":"crossref","unstructured":"Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337:809\u2013815","DOI":"10.1056\/NEJM199709183371202"},{"key":"atypb25","doi-asserted-by":"crossref","unstructured":"Song F: Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 1997; 11:65\u201371","DOI":"10.1177\/026988119701100116"},{"key":"atypb26","doi-asserted-by":"crossref","unstructured":"Azorin JM: Long-term treatment of mood disorders in schizophrenia. Acta Psychiatr Scand Suppl 1995; 91:20\u201323","DOI":"10.1111\/j.1600-0447.1995.tb05940.x"},{"key":"R1579BABHFBEE","doi-asserted-by":"crossref","unstructured":"Ceskova E, Svestka J: Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26:121\u2013124","DOI":"10.1055\/s-2007-1014355"},{"key":"atypb27","doi-asserted-by":"crossref","unstructured":"Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, Tollefson GD: Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17:407\u2013418","DOI":"10.1097\/00004714-199710000-00010"},{"key":"R1579BABJJCHF","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Sanger TM, Lu Y, Thieme ME: Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998; 55:250\u2013258","DOI":"10.1001\/archpsyc.55.3.250"},{"key":"atypb28","doi-asserted-by":"crossref","unstructured":"Tollefson GD, Sanger TM, Beasley CM, Tran PV: A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998; 43:803\u2013810","DOI":"10.1016\/S0006-3223(98)00093-6"},{"key":"R1579BABGBGBJ","doi-asserted-by":"crossref","unstructured":"Keck P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR: Ziprasidone 40 and 120 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140:173\u2013184","DOI":"10.1007\/s002130050755"},{"key":"atypb29","doi-asserted-by":"crossref","unstructured":"Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M (Ziprasidone Study Group): Ziprasidone 80 mg\/day and 160 mg\/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20:491\u2013505","DOI":"10.1016\/S0893-133X(98)00090-6"},{"key":"atypb30","doi-asserted-by":"crossref","unstructured":"Meltzer HY, Okayli G: Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152:183\u2013190","DOI":"10.1176\/ajp.152.2.183"},{"key":"atypb31","doi-asserted-by":"crossref","unstructured":"Walker AM, Lanza LL, Arellano F, Rothman KJ: Mortality in current and former users of clozapine. Epidemiology 1998; 8:671\u2013679","DOI":"10.1097\/00001648-199710000-00010"},{"key":"atypb32","doi-asserted-by":"crossref","unstructured":"Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261\u2013276","DOI":"10.1093\/schbul\/13.2.261"},{"key":"atypb33","doi-asserted-by":"crossref","unstructured":"Montgomery SA, \u00c5sberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134:382\u2013389","DOI":"10.1192\/bjp.134.4.382"},{"key":"R1579BABJIIIF","doi-asserted-by":"crossref","unstructured":"Klein DF: Psychiatric diagnosis and a typology of clinical drug effects. Psychopharmacologia 1968; 13:359\u2013386","DOI":"10.1007\/BF00404952"},{"key":"atypb34","doi-asserted-by":"crossref","unstructured":"Robertson MM, Trimble MR: Major tranquilizers used as antidepressants: a review. J Affect Disord 1982; 4:173\u2013193","DOI":"10.1016\/0165-0327(82)90002-7"},{"key":"atypb35","doi-asserted-by":"crossref","unstructured":"Goldman RS, Tandon R, Liberzon I, Greden JF: Measurement of depression and negative symptoms in schizophrenia. Psychopathology 1992; 25:49\u201356","DOI":"10.1159\/000284753"},{"key":"R1579BABBDDCD","unstructured":"Mauri MC, Bravin S, Fabiano L, Vanni S, Boscati L, Invernizzi G: Depressive symptoms and schizophrenia: a psychopharmacological approach. Encephale 1995; 21:555\u2013558"},{"key":"R1579BABBGGJJ","unstructured":"Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56:423\u2013429"},{"key":"R1579BABBGEAJ","unstructured":"Zarate CA, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411\u2013417"},{"key":"R1579BABGEBBD","doi-asserted-by":"crossref","unstructured":"Hillert A, Maier W, Wetzel H, Benkert O: Risperidone in the treatment of disorders with a combined psychotic and depressive syndrome\u2014a functional approach. Pharmacopsychiatry 1992; 25:213\u2013217","DOI":"10.1055\/s-2007-1014408"},{"key":"atypb37","unstructured":"Keck PE, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePriest M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56:466\u2013470"},{"key":"atypb38","doi-asserted-by":"crossref","unstructured":"Parsa MA, Ramirez LF, Loula EC, Meltzer HY: Effect of clozapine on psychotic depression and parkinsonism. J Clin Psychopharmacol 1991; 11:330\u2013331","DOI":"10.1097\/00004714-199110000-00019"},{"key":"atypb39","doi-asserted-by":"crossref","unstructured":"Ranjan R, Meltzer HY: Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry 1996; 40:253\u2013258","DOI":"10.1016\/0006-3223(95)00305-3"},{"key":"atypb40","doi-asserted-by":"crossref","unstructured":"Weisler RH, Ahearn EP, Davidson JR, Wallace CD: Adjunctive use of olanzapine in mood disorders: five case reports. Ann Clin Psychiatry 1997; 9:259\u2013262","DOI":"10.3109\/10401239709147807"},{"key":"atypb41","doi-asserted-by":"crossref","unstructured":"Lindstrom E, von Knorring L: Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 1994; 27:108\u2013113","DOI":"10.1055\/s-2007-1014288"},{"key":"atypb42","doi-asserted-by":"crossref","unstructured":"Marder SR, Davis JM, Chouinard G: The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538\u2013546","DOI":"10.4088\/JCP.v58n1205"},{"key":"R1579BABDHHDI","doi-asserted-by":"crossref","unstructured":"Young CR, Longhurst JG, Bowers M, Mazure C: The expanding indications for clozapine. Exp Clin Psychopharmacol 1997; 5:216\u2013234","DOI":"10.1037\/\/1064-1297.5.3.216"},{"key":"R1579BABCEEGJ","doi-asserted-by":"crossref","unstructured":"Waddington JL, Scully PJ, O\u2019Callighan E: The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophr Res 1997; 28:207\u2013222","DOI":"10.1016\/S0920-9964(97)00115-1"},{"key":"R1579BABJHICH","doi-asserted-by":"crossref","unstructured":"Pandey GN, Pandey SC, Janicak PG, Marks RC, Davis JM: Platelet serotonin-2 receptor binding sites in depression and suicide. Biol Psychiatry 1990; 28:215\u2013222","DOI":"10.1016\/0006-3223(90)90576-N"},{"key":"R1579BABIEABA","doi-asserted-by":"crossref","unstructured":"Fleischhacker WW, Roth SD, Kane JM: The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990; 10:12\u201321","DOI":"10.1097\/00004714-199002000-00003"},{"key":"R1579BABBDACH","doi-asserted-by":"crossref","unstructured":"Dilsaver SC, Coffman JA: Cholinergic hypothesis of depression: a reappraisal. J Clin Psychopharmacol 1989; 9:173\u2013179","DOI":"10.1097\/00004714-198906000-00003"},{"key":"R1579BABIIIAF","doi-asserted-by":"crossref","unstructured":"Tandon R, Greden JF: Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry 1989; 46:745\u2013753","DOI":"10.1001\/archpsyc.1989.01810080075010"},{"key":"R1579BABHHHIB","doi-asserted-by":"crossref","unstructured":"Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB: Adjunctive imipramine in the treatment of post-psychotic depression: a controlled trial. Arch Gen Psychiatry 1987; 44:533\u2013539","DOI":"10.1001\/archpsyc.1987.01800180043008"},{"key":"atypb43","doi-asserted-by":"crossref","unstructured":"Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J: Pharmacotherapy of impaired affect in recovering schizophrenic patients. Arch Gen Psychiatry 1995; 52:29\u201341","DOI":"10.1001\/archpsyc.1995.03950130029004"},{"key":"R1579BABIIBFB","doi-asserted-by":"crossref","unstructured":"Plasky P: Antidepressant usage in schizophrenia. Schizophr Bull 1991; 17:649\u2013657","DOI":"10.1093\/schbul\/17.4.649"},{"key":"R1579BABEFABA","doi-asserted-by":"crossref","unstructured":"Levinson DF, Umapathy C, Musthaq M: Treatment of schizoaffective disorder and schizophrenia with mood symptoms. Am J Psychiatry 1999; 156:1138\u20131148","DOI":"10.1176\/ajp.156.8.1138"},{"key":"R1579BABCCBIC","doi-asserted-by":"crossref","unstructured":"Goff DC, Brotman AW, Waltes M, McCormick S: Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. Am J Psychiatry 1990; 147:492\u2013494","DOI":"10.1176\/ajp.147.4.492"},{"key":"R1579BABEEFGG","doi-asserted-by":"crossref","unstructured":"Evins AE, Goff DC: Adjunctive antidepressant drug therapies in the treatment of negative symptoms of schizophrenia. Drug Therapy 1996; 6:130\u2013147","DOI":"10.2165\/00023210-199606020-00005"},{"key":"R1579BABJEIIC","unstructured":"Brenner R, Shopsin B: The use of monoamine oxidase inhibitors in schizophrenia. Biol Psychiatry 1980; 15:633\u2013647"},{"key":"atypb44","doi-asserted-by":"crossref","unstructured":"Silver H, Nassar A: Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 1992; 31:698\u2013704","DOI":"10.1016\/0006-3223(92)90279-9"},{"key":"atypb45","doi-asserted-by":"crossref","unstructured":"Spina E, DeDomenico P, Ruello C, Longobardo N, Gitto C, Ancione M, DiRosa AE, Caputi AP: Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. Int Clin Psychopharmacol 1994; 9:281\u2013285","DOI":"10.1097\/00004850-199400940-00007"},{"key":"atypb46","doi-asserted-by":"crossref","unstructured":"Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E: A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology (Berl) 1995; 117:417\u2013423","DOI":"10.1007\/BF02246213"},{"key":"atypb47","doi-asserted-by":"crossref","unstructured":"Salokangas RKR, Saarijarvi S, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Ahola V, Syvalahti E: Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94:175\u2013180","DOI":"10.1111\/j.1600-0447.1996.tb09844.x"},{"key":"R1579BABIFJCH","doi-asserted-by":"crossref","unstructured":"Silver H, Shmugliakov N: Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. J Clin Psychopharmacol 1998; 18:208\u2013211","DOI":"10.1097\/00004714-199806000-00005"},{"key":"R1579BABCFGJA","doi-asserted-by":"crossref","unstructured":"Bucci L: The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology (Berl) 1987; 91:104\u2013108","DOI":"10.1007\/BF00690936"},{"key":"atypb48","doi-asserted-by":"crossref","unstructured":"Bodkin AJ, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO: Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. J Nerv Ment Dis 1996; 184:295\u2013301","DOI":"10.1097\/00005053-199605000-00005"},{"key":"R1579BABCADAJ","doi-asserted-by":"crossref","unstructured":"Perenyi A, Goswami U, Frecska E, Arato M: l-Deprenyl in treating negative symptoms of schizophrenia. Psychiatry Res 1992; 42:189\u2013191","DOI":"10.1016\/0165-1781(92)90082-E"},{"key":"R1579BABHCDJH","doi-asserted-by":"crossref","unstructured":"Decina P, Mukherjee S, Bocola V, Saraceni F, Hadjichristos C, Scapicchio P: Adjunctive trazodone in the treatment of negative symptoms of schizophrenia. Hosp Community Psychiatry 1994; 45:1220\u20131223","DOI":"10.1176\/ps.45.12.1220"},{"key":"R1579BABBIIDB","doi-asserted-by":"crossref","unstructured":"Christison GW, Kirch DG, Wyatt RJ: When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 1991; 17:217\u2013240","DOI":"10.1093\/schbul\/17.2.217"},{"key":"R1579BABBEDBJ","doi-asserted-by":"crossref","unstructured":"Lerner Y, Mintzer Y, Schestatzky M: Lithium combined with haloperidol in schizophrenic patients. Br J Psychiatry 1988; 153:359\u2013362","DOI":"10.1192\/bjp.153.3.359"},{"key":"R1579BABGDAGF","unstructured":"Atre-Vaidya N, Taylor MA: Effectiveness of lithium in schizophrenia: do we really have an answer? J Clin Psychiatry 1989; 50:170\u2013173"},{"key":"R1579BABGFBJH","doi-asserted-by":"crossref","unstructured":"Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, Madonia MJ: Family psychoeducational, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia, 1: one-year effects of a controlled study on relapse and expressed emotion. Arch Gen Psychiatry 1986; 43:633\u2013642","DOI":"10.1001\/archpsyc.1986.01800070019003"}],"container-title":["American Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.157.9.1379","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T14:14:01Z","timestamp":1722176041000},"score":1,"resource":{"primary":{"URL":"https:\/\/psychiatryonline.org\/doi\/10.1176\/appi.ajp.157.9.1379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9,1]]},"references-count":145,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2000,9,1]]}},"alternative-id":["10.1176\/appi.ajp.157.9.1379"],"URL":"https:\/\/doi.org\/10.1176\/appi.ajp.157.9.1379","relation":{},"ISSN":["0002-953X","1535-7228"],"issn-type":[{"value":"0002-953X","type":"print"},{"value":"1535-7228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,9,1]]}}}